Drug Profile
AAV2sFLT 01 - Beacon Therapeutics
Alternative Names: AAV2-sFLT01; age-related macular degeneration gene therapy - Beacon Therapeutics; anti vascular endothelial growth factor (VEGF) gene therapy - Beacon Therapeutics; GZ-402663; sFLT-01Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Applied Genetic Technologies Corporation; Genzyme Corporation
- Developer Beacon Therapeutics; JDRF; Sanofi
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Age-related macular degeneration
- Discontinued Diabetic retinopathy
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in USA (Intravitreous, Injection)
- 01 Jul 2018 Phase I development in Age-related macular degeneration is ongoing in USA (Intravitreous) (NCT01024998)
- 01 Jul 2018 Genzyme completes a phase I trial in Age-related macular degeneration in USA (Intravitreous) (NCT01024998)